A New Way to Prevent a Second Stroke? What the OCEANIC-STROKE Trial Means for Survivors
A major clinical trial suggests that a new medication could help prevent second strokes without significantly increasing major bleeding. Here's what stroke survivors and caregivers should know.
For many stroke survivors, one of the biggest worries during recovery is whether another stroke might happen.
Preventing a second stroke is an essential part of recovery. Fortunately, medications and lifestyle changes can substantially reduce that risk. Now, results from a major clinical trial suggest that another treatment may eventually become available.
The medication, called asundexian, reduced the risk of another ischemic stroke by approximately 26% when added to standard treatment. Importantly, it did so without a statistically significant increase in major bleeding.
The findings, published in The New England Journal of Medicine in April 2026, are promising. However, asundexian is still being evaluated by the FDA and is not an established treatment for stroke prevention.
What Did the OCEANIC-STROKE Trial Find?
The OCEANIC-STROKE trial followed more than 12,000 people who had recently experienced an ischemic stroke or a high-risk transient ischemic attack (TIA), sometimes called a mini-stroke.
An ischemic stroke occurs when a blood clot blocks blood flow to part of the brain. A TIA causes temporary stroke-like symptoms and is an important warning sign of future stroke risk.
Participants were already receiving standard medications to prevent blood clots. Researchers then gave half the participants asundexian and the other half a placebo.
After approximately 19 months, the results showed:
Risk of another ischemic stroke:
6.2%Â among people taking asundexian.
8.4%Â among people receiving a placebo.
This represents a 26% relative reduction in stroke risk.
In everyday terms, for every 1,000 people similar to those in the study, approximately 22 fewer people experienced another ischemic stroke in the asundexian group over the study period.
That is a meaningful improvement, particularly because another stroke can cause additional disability and interrupt recovery.
What About the Risk of Bleeding?
This may be the most encouraging part of the study.
Medications that prevent blood clots can also increase bleeding. This creates a difficult balance for doctors trying to prevent another stroke.
In OCEANIC-STROKE, major bleeding occurred in:
1.9%Â of people receiving asundexian.
1.7%Â of people receiving a placebo.
The difference was not statistically significant.
This suggests that asundexian may help prevent dangerous blood clots without substantially increasing the risk of major bleeding.
However, this does not mean that the medication is free from bleeding risks. Longer-term safety monitoring remains important, and some types of bleeding may still be more common.
How Does Asundexian Work?
Asundexian works differently from many existing stroke-prevention medications.
It blocks a blood-clotting protein called factor XIa.
Factor XIa helps blood clots grow and become more stable. By blocking this protein, researchers hope to reduce harmful clot formation while preserving more of the body's normal ability to stop bleeding after an injury.
This is why the drug has generated considerable interest.
For years, researchers have been looking for ways to prevent strokes without increasing bleeding risk. Asundexian may offer a new approach for certain patients.
Is Asundexian Suitable for Everyone Who Has Had a Stroke?
No. This is an important limitation of the study.
OCEANIC-STROKE focused on people who had recently experienced a noncardioembolic ischemic stroke or high-risk TIA.
This means their stroke was not believed to have been caused by a blood clot forming in the heart.
The study does not establish that asundexian is suitable for everyone who has experienced a stroke, particularly people with:
Atrial fibrillation (AFib):Â An irregular heartbeat that can cause blood clots to form inside the heart.
Hemorrhagic stroke:Â A stroke caused by bleeding in the brain rather than a blocked blood vessel.
A stroke many months or years ago:Â The trial started treatment within 72 hours of the initial stroke or TIA.
In fact, another major study found that asundexian was less effective than apixaban (Eliquis) at preventing strokes and other clot-related events in people with atrial fibrillation.
For this reason, people taking anticoagulants for atrial fibrillation should not switch medications because of the OCEANIC-STROKE findings.
The best medication depends on what caused the original stroke and each person's medical history.
Is Asundexian Available Now?
Asundexian is under review by the U.S. Food and Drug Administration (FDA).
In May 2026, the FDA accepted an application to review the medication and granted it Priority Review, a process intended to speed the evaluation of potentially important new treatments.
Priority Review does not mean a medication has been approved.
If asundexian is approved, doctors will need to follow the FDA's prescribing guidance to determine which stroke survivors may benefit.
For now, stroke survivors should continue their prescribed medications and should not make changes based on this trial.
What Can You Do Today to Reduce Your Risk of Another Stroke?
Although new treatments are encouraging, several proven ways to lower stroke risk are already available.
The most useful step is to work with your healthcare team to understand what caused your stroke and how to reduce the chances of another one.
Important steps include:
Control blood pressure. High blood pressure is one of the most important preventable risk factors for stroke.
Take prescribed medications. Aspirin, clopidogrel, anticoagulants, cholesterol-lowering medications, and other treatments can help when used appropriately.
Manage cholesterol and diabetes. Keeping these conditions under control protects blood vessels.
Stop smoking. Quitting can substantially improve cardiovascular health.
Stay physically active. Work with your rehabilitation team to identify safe activities that match your abilities.
Attend follow-up appointments. Regular checkups help identify problems and adjust treatment when necessary.
If you are having difficulty taking medications because of side effects, cost, or confusion about your schedule, talk to your healthcare team rather than stopping treatment.
Questions to Ask Your Doctor
The OCEANIC-STROKE findings offer a useful opportunity to review your stroke-prevention plan.
At your next appointment, consider asking:
What caused my stroke? Was it related to a narrowed artery, a heart condition, or something else?
Am I taking the right medications to prevent another stroke?
Are my blood pressure and cholesterol at the recommended levels?
Do I need additional testing for atrial fibrillation or another underlying cause?
What else can I do to reduce my risk?
Understanding your individual risk factors is one of the best ways to take an active role in recovery.
The Bottom Line
The OCEANIC-STROKE trial offers encouraging evidence that a new medication could help prevent recurrent ischemic strokes.
By reducing stroke risk without a statistically significant increase in major bleeding, asundexian may represent an important advance in stroke prevention.
However, it is not appropriate for every type of stroke, and its role in routine medical care is still being determined.
For stroke survivors, the most important message remains the same:Â preventing another stroke is part of recovery.
Rehabilitation helps the brain recover from an injury that has already occurred. Effective stroke prevention helps protect that progress and gives survivors the best opportunity for continued recovery.
References
Sharma M, Dong Q, Hirano T, et al. Asundexian for Secondary Stroke Prevention. New England Journal of Medicine. 2026;394:1467–1479. https://doi.org/10.1056/NEJMoa2513880
Piccini JP, Patel MR, Steffel J, et al. Asundexian versus Apixaban in Patients with Atrial Fibrillation. New England Journal of Medicine. 2025;392:23–32. https://doi.org/10.1056/NEJMoa2407105
Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke. 2021;52–e467. https://doi.org/10.1161/STR.0000000000000375
Disclosure and Medical Disclaimer
Rebuild After Stroke is an independent nonprofit organization dedicated to providing accessible, evidence-based information for stroke survivors and caregivers. This article is provided for educational purposes and does not constitute medical advice. The OCEANIC-STROKE trial was funded by Bayer, the manufacturer of asundexian. This article is not sponsored by Bayer and does not endorse any particular medication.
Stroke prevention should always be individualized with a qualified healthcare professional. Never start, stop, or change prescribed medications without medical guidance. If you or someone else develops sudden symptoms of stroke, call 911 immediately.
Comments